Press releases

GeNeuro publishes its 2021 Universal Registration Document

Geneva, Switzerland, April 27, 2022 – 6:00 pm CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), publishes its 2021 Universal Registration Document, in English, which has been filed on April 27, 2022 with the “Autorité des Marchés Financiers (AMF)”.

https://geneuro.ch/data/news/GeNeuro-PR-Mise-a-dispo-URD-2021-EN.pdf

GeNeuro: financial information for the first quarter 2022

Geneva, Switzerland, April 15, 2022 – 7.30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 first quarter cash position.

https://geneuro.ch/data/news/GeNeuro-PR-Q1-2022-EN.pdf

GeNeuro and FondaMental Foundation announce the first results of the collaboration for the development of diagnostic and therapeutic options for patients with post-COVID neuropsychiatric syndromes

Geneva, Switzerland, April 13, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), and the FondaMental Foundation, a scientific cooperation foundation serving patients with mental illness, presented at the Schizophrenia International Research Society (SIRS) congress from April 6 to 10 in Florence, Italy, the first data resulting from their collaboration launched in 2021, in the context of COVID.

https://geneuro.ch/data/news/2022.04.13-GeNeuro-PR-04132022-Psy-Results-ENG-vf.pdf

GeNeuro Reports 2021 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 4, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), reports today its full-year results for the year ended December 31, 2021 and provided a corporate update.

https://geneuro.ch/data/news/2022.04.04-GeNeuro-PR-April-4-2022-FY-2021-results.pdf

GeNeuro announces the completion of its ProTEct-MS study and confirms the March timeline for top-line results, provides a Business Update and Cash Position as of December 31, 2021

Geneva, Switzerland, January 27, 2022 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update.

https://geneuro.ch/data/news/2022.01.27-GeNeuro-PR-FY-2021-EN-vf-1-.pdf

Presentation at The Lancet Summit on GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

Geneva, Switzerland, December 20, 2021 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that its Chief Scientific Officer, Dr. Hervé Perron, unveiled today at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH).

https://geneuro.ch/data/news/2021.12.20-PR-GeNeuro-presentation-at-Lancet-Summit-EN-VF.pdf